MaRS client, Kalgene, sees some cash
Kalgene Diagnostics (a division of Kalgene Pharmaceuticals – a MaRS client company and incubator tenant) has just raised $500,ooo from the PARTEQ Venture Fund to develop novel diagnostic tests for cancer. PARTEQ Venture Fund is a provincially sponsored investment fund set up by PARTEQ Innovations. See the news release, “Four Kingston startup companies receive $1.6 million vote of confidence”.
According to Dr. Nathan Yoganathan (Kalgene CEO) the company raised a total of $1.5 million in 2009 from private investors – no mean feat in these challenging times.
Kalgene is an oncology company which develops cancer therapeutics and companion diagnostics with the goal of providing personalized treatments for cancer patients. Kalgene’s lead therapeutic program is for bladder cancer (Phase III in EU).
John provides assistance to life sciences entrepreneurs in business strategy, management, intellectual property, financing and licensing.
